Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 3Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Antineoplastic Agents × Clear all
NCT06877533 2025-08-12

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

iTeos Therapeutics

Phase 1 Terminated
3 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡